Vol 2, No 1 (1999)
Original articles
Published online: 2000-02-22
Submitted: 2012-01-23
Get Citation

Quantification of breast cancer blood flow in absolute units using Gjedde-Rutland-Patlak analysis of 99mTc-MIBI uptake

Waldimir Yu. Ussov, Julia E. Riannel, Elena M. Slonimskaya, Svetlana A. Velichko, Sergey D. Kalashnikov Jasna Milos Mihailovic, Frencesco Scopinaro
Nucl. Med. Rev 1999;2(1):4-9.
Vol 2, No 1 (1999)
Original articles
Published online: 2000-02-22
Submitted: 2012-01-23

Abstract

Background: Scintimammography with 99mTc-MIBI has been proven as efficient technique of diagnosis of breast cancer. Nevertheless, quantification of breast carcinoma blood flow (BCBF) in absolute units is not yet developed. To compensate this, we analysed kinetics of 99mTc-MIBI uptake in breast cancer using Gjedde-Rutland-Patlak (GRP) approach.
Methods: If BC is radioactivity in breast cancer quantified by dynamic scintigraphy, Ch-blood concentration of 99mTc-MIBI and K - transport constant, then, assuming 99mTc-MIBI uptake to breast carcinoma unidirectional for early minutes after injection and subjected to equation d(BC)/dt = K ´ Ch, classic GRP plot can be obtained from this by integration as BC/Ch=K´(ňChdt)/Ch + V0 and placing {(ňChdt)/Ch} as X, and (A/Ch) as Y. The K can be then obtained as slope. K is breast cancer clearance equal to product (retention fraction) ´ (blood flow) : K = E ´ BCBF. K can be calculated from A(t) and Ch(t) as asymptote of 99mTc-MIBI retention function h(t) = F-1{F[A(t)]/F[Ch(t)]}, where F depicts Fourier transforms. The BCBF can be then obtained as ratio K/E. We employed the technique in 33 patients with breast carcinoma of stages T1-3N0-3M0-1 injecting 99mTc-MIBI (370-510 MBq) as i.v. bolus. In 12 scintigraphy with 99mTc-MAA (370 MBq) injected via catheter intraaortically was performed as validation study.
Results: E values were essentially uniform over the population with overall mean 0.58 sd 0.06. Blood clearance curves did not differ between various stages also and were subjected to biexponential approximation. K was in all cases obtained from the slope of initial 3 min part of GRP plot, strongly linear (r > 0.95, p < 0.001) in all cases. 99mTc-MAA validation study revealed significant correlation with 99mTc-MIBI blood flow values (r = 0.94, p < 0.01). The BCBF(as ml/min/100 cm3) was in T1 12,85 sd. 4,76, in T2 15,87 sd. 1,78, in T3 17,35 sd. 2,45, and in T4 23,07 sd. 2,21, expressing tendency to increase with stage. Higher BCBF was significantly associated with metastatic spread and in patients with BCBF over 17 ml/min/100 cm3 distant mets were revealed in all cases.
Conclusion: Hence, analysis of early kinetics of 99mTc-MIBI in breast carcinoma provides correct estimates of blood flow in the neoplasm and can be applied in clinical studies and for calculation of cytostatic delivery to BC.

Abstract

Background: Scintimammography with 99mTc-MIBI has been proven as efficient technique of diagnosis of breast cancer. Nevertheless, quantification of breast carcinoma blood flow (BCBF) in absolute units is not yet developed. To compensate this, we analysed kinetics of 99mTc-MIBI uptake in breast cancer using Gjedde-Rutland-Patlak (GRP) approach.
Methods: If BC is radioactivity in breast cancer quantified by dynamic scintigraphy, Ch-blood concentration of 99mTc-MIBI and K - transport constant, then, assuming 99mTc-MIBI uptake to breast carcinoma unidirectional for early minutes after injection and subjected to equation d(BC)/dt = K ´ Ch, classic GRP plot can be obtained from this by integration as BC/Ch=K´(ňChdt)/Ch + V0 and placing {(ňChdt)/Ch} as X, and (A/Ch) as Y. The K can be then obtained as slope. K is breast cancer clearance equal to product (retention fraction) ´ (blood flow) : K = E ´ BCBF. K can be calculated from A(t) and Ch(t) as asymptote of 99mTc-MIBI retention function h(t) = F-1{F[A(t)]/F[Ch(t)]}, where F depicts Fourier transforms. The BCBF can be then obtained as ratio K/E. We employed the technique in 33 patients with breast carcinoma of stages T1-3N0-3M0-1 injecting 99mTc-MIBI (370-510 MBq) as i.v. bolus. In 12 scintigraphy with 99mTc-MAA (370 MBq) injected via catheter intraaortically was performed as validation study.
Results: E values were essentially uniform over the population with overall mean 0.58 sd 0.06. Blood clearance curves did not differ between various stages also and were subjected to biexponential approximation. K was in all cases obtained from the slope of initial 3 min part of GRP plot, strongly linear (r > 0.95, p < 0.001) in all cases. 99mTc-MAA validation study revealed significant correlation with 99mTc-MIBI blood flow values (r = 0.94, p < 0.01). The BCBF(as ml/min/100 cm3) was in T1 12,85 sd. 4,76, in T2 15,87 sd. 1,78, in T3 17,35 sd. 2,45, and in T4 23,07 sd. 2,21, expressing tendency to increase with stage. Higher BCBF was significantly associated with metastatic spread and in patients with BCBF over 17 ml/min/100 cm3 distant mets were revealed in all cases.
Conclusion: Hence, analysis of early kinetics of 99mTc-MIBI in breast carcinoma provides correct estimates of blood flow in the neoplasm and can be applied in clinical studies and for calculation of cytostatic delivery to BC.
Get Citation

Keywords

99mTc-MIBI; breast cancer; blood flow; scintimammography; Gjedde-Rutland-Patlak analysis

About this article
Title

Quantification of breast cancer blood flow in absolute units using Gjedde-Rutland-Patlak analysis of 99mTc-MIBI uptake

Journal

Nuclear Medicine Review

Issue

Vol 2, No 1 (1999)

Pages

4-9

Published online

2000-02-22

Bibliographic record

Nucl. Med. Rev 1999;2(1):4-9.

Keywords

99mTc-MIBI
breast cancer
blood flow
scintimammography
Gjedde-Rutland-Patlak analysis

Authors

Waldimir Yu. Ussov
Julia E. Riannel
Elena M. Slonimskaya
Svetlana A. Velichko
Sergey D. Kalashnikov Jasna Milos Mihailovic
Frencesco Scopinaro

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., Świętokrzyska 73 street, 80–180 Gdańsk, Poland

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl